Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06079372 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa
A Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 43
- Enrollment target
- 20
- Study locations
NCT06079372: Active Phase 3 study of Hypophosphatasia, sponsored by Alexion Pharmaceuticals.
NCT06079372 is a Phase 3 study of Hypophosphatasia that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 43 participants, below the 77-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06079372, a Phase 3 study of Hypophosphatasia, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 43 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
Conditions Studied
Interventions
- DRUG ALXN1850
- DRUG asfotase alfa
Study Locations (20)
Other
- Research Site - Mar del Plata
- Research Site - South Brisbane
- Research Site - Bunkyō City
- Research Site - Minatoku
- Research Site - Suita-shi
- Research Site - Yonago-shi
- Research Site - Altındağ
- Research Site - Ankara
- Research Site - Edirne
- Research Site - Erzurum
- Research Site - Istanbul
- Research Site - Birmingham
- Research Site - Manchester
Connecticut
- Research Site - Hartford
Maryland
- Research Site - Baltimore
Minnesota
- Research Site - Minneapolis
Missouri
- Research Site - Kansas City
North Carolina
- Research Site - Durham
Tennessee
- Research Site - Nashville
Ontario
- Research Site - Ottawa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 3 |
What the registry record for NCT06079372 still lists
NCT06079372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 77-participant average among 6 other Hypophosphatasia trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Hypophosphatasia appearing as the primary indexed condition, and to 2 interventions - of which ALXN1850 is the first listed.
NCT06079372 names 20 study sites across 8 states, led by Other, Connecticut, Maryland.
Frequently Asked Questions
What is clinical trial NCT06079372 about?
NCT06079372 is a clinical study titled "Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa". The primary purpose of this study is to assess the safety and tolerability of ALXN1850 versus asfotase alfa in pediatric participants with HPP previously treated with asfotase alfa.
What is the current status of trial NCT06079372?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 43 participants. The study started on 2024-04-02. Estimated completion is 2028-02-29.
What conditions does trial NCT06079372 study?
This clinical trial studies the following conditions: Hypophosphatasia.
What interventions are being tested in trial NCT06079372?
The interventions under investigation include: ALXN1850 (DRUG), asfotase alfa (DRUG).
Who is sponsoring clinical trial NCT06079372?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06079372 being conducted?
This trial has 20 study locations across Connecticut, Maryland, Minnesota, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypophosphatasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa
ACTIVE NOT RECRUITING · Phase 3
-
United States Hypophosphatasia Molecular Research Center
RECRUITING
-
Natural History Study of Patients With Hypophosphatasia (HPP)
RECRUITING
-
A Prospective Sub-Study of the Global Hypophosphatasia Registry
RECRUITING
-
Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI